TriMix, a new multiple-action tear substitute, significantly improves symptoms of dry eye disease (DED) compared to a standard hyaluronic acid tear substitute, with a favorable safety profile, according to a study. The results indicate that TriMix could be a promising treatment for DED, but further research is needed to confirm its long-term effectiveness.
The study included 115 patients, who were randomly assigned to receive either TriMix or a standard 0.15% hyaluronic acid (HA) tear substitute 3 times daily.
At both 3 and 6 months, patients using TriMix showed significant improvements compared to the HA group. TriMix led to a greater reduction in Ocular Surface Disease Index scores (-3.7 points at 3 months and -7.5 points at 6 months), as well as improved non-invasive tear film break-up time (0.9 seconds at 3 months and 1.6 seconds at 6 months).
No serious ocular adverse events were reported, although 3 patients experienced mild burning upon application of the TriMix tear substitute.
Reference
Ballesteros-Sánchez A, Tedesco GR, Rocha-de-Lossada C, et al. Efficacy and safety of a multi-action tear substitute based on 0.15% cross-linked hyaluronic acid, 3% trehalose and liposomes with stearylamine: A randomized, single-mask, controlled study. Graefes Arch Clin Exp Ophthalmol. 2025;doi: 10.1007/s00417-025-06765-1. Epub ahead of print. PMID: 39934351.
Related Content
